Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3D21X)

Drug Name

ML218 Drug Info

Synonyms

ML-218; ML 218

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 45115620
ChEBI ID: CHEBI:91745
TTD Drug ID: DM3D21X

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Preclinical Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sodium bicarbonate	DMMU6BJ	Metabolic acidosis	5C73	Approved	[3]
Flunarizine	DMZU5JP	Migraine	8A80	Approved	[4]
ABT-639	DMEWQ4X	Pain	MG30-MG3Z	Phase 2	[5]
Mibefradil	DMU9VDS	Glioblastoma multiforme	2A00.0	Phase 1	[6]
TTA-A8	DMWZCIF	Insomnia	7A00-7A0Z	Preclinical	[7]
U-92032	DMTYO3P	N. A.	N. A.	Terminated	[8]
KYS-05001	DM3MID9	Discovery agent	N.A.	Investigative	[9]
KYS-05077	DMHW40F	Discovery agent	N.A.	Investigative	[10]
KYS-05080	DM57BXZ	Discovery agent	N.A.	Investigative	[10]
Cis-N,5-dibenzyl-6-oxomorpholine-3-carboxamide	DM75SO4	Discovery agent	N.A.	Investigative	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[12]
Ethosuximide	DMDZ9LT	Epilepsy	8A60-8A68	Approved	[13]
Trimethadione	DM0Q8MZ	Absence epilepsy		Approved	[14]
Paramethadione	DMR5ZUP	Absence epilepsy		Approved	[14]
Methsuximide	DM6L5VO	Absence epilepsy		Approved	[15]
Penfluridol	DMG1DTE	Schizophrenia	6A20	Approved	[16]
PD-200390	DMPW28M	Insomnia	7A00-7A0Z	Phase 2	[17]
NGD 94-1	DMM1Y8F	Schizophrenia	6A20	Phase 1	[16]
KYS-05001	DM3MID9	Discovery agent	N.A.	Investigative	[18]
KYS-05077	DMHW40F	Discovery agent	N.A.	Investigative	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Voltage-gated calcium channel alpha Cav3.3 (CACNA1I)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
U-92032	DMTYO3P	N. A.	N. A.	Terminated	[8]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Voltage-gated calcium channel alpha Cav3.1 (CACNA1G)	TT729IR	CAC1G_HUMAN	Blocker (channel blocker)	[2]
Voltage-gated calcium channel alpha Cav3.2 (CACNA1H)	TTZPWGN	CAC1H_HUMAN	Blocker (channel blocker)	[2]
Voltage-gated calcium channel alpha Cav3.3 (CACNA1I)	TTQZFTH	CAC1I_HUMAN	Blocker (channel blocker)	[2]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7720).
2	The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's Disease. ACS Chem Neurosci. 2011 Dec 21;2(12):730-742.
3	Acute renal failure. Clin Evid (Online). 2008 Sep 3;2008. pii: 2001.
4	Positive allosteric interaction of structurally diverse T-type calcium channel antagonists. Cell Biochem Biophys. 2009;55(2):81-93.
5	Effects of a T-type calcium channel blocker, ABT-639, on spontaneous activity in C-nociceptors in patients with painful diabetic neuropathy: a randomized controlled trial. Pain. 2015 Nov;156(11):2175-83.
6	Mibefradil block of cloned T-type calcium channels. J Pharmacol Exp Ther. 2000 Oct;295(1):302-8.
7	Short-acting T-type calcium channel antagonists significantly modify sleep architecture in rodents. ACS Med Chem Lett. 2010 Aug 24;1(9):504-9.
8	Discovery of (2S)-1-(4-amino-2,3,5- trimethylphenoxy)-3-[4-[4-(4- fluorobenzyl)phenyl]-1-piperazinyl]-2-propanol dimethanesulfonate (SUN N8075): a ... J Med Chem. 2000 Sep 7;43(18):3372-6.
9	3,4-Dihydroquinazoline derivatives as novel selective T-type Ca2+ channel blockers. Bioorg Med Chem Lett. 2004 Jul 5;14(13):3379-84.
10	Synthesis and biological evaluation of novel T-type calcium channel blockers. Bioorg Med Chem Lett. 2007 Jan 15;17(2):471-5.
11	Morpholin-2-one derivatives as novel selective T-type Ca2+ channel blockers. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5244-8.
12	Mechanism of tissue-selective drug action in the cardiovascular system. Mol Interv. 2005 Apr;5(2):84-93.
13	Maladaptive homeostatic plasticity in a rodent model of central pain syndrome: thalamic hyperexcitability after spinothalamic tract lesions. J Neurosci. 2008 Nov 12;28(46):11959-69.
14	Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res. 2007 Apr;226(1-2):52-60.
15	Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol. 2001 Nov;60(5):1121-32.
16	Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci. 2002 Jan 15;22(2):396-403.
17	Pfizer. Product Development Pipeline. March 31 2009.
18	Discovery of potent T-type calcium channel blocker. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5740-3.